Article ID Journal Published Year Pages File Type
9216731 Oral Oncology 2005 7 Pages PDF
Abstract
The combination of docetaxel and cisplatin is active in metastatic NPC. The dose of 60 mg/m2 for both drugs without colony-stimulating factor support should be further evaluated as a high incidence of febrile neutropenia was observed with 75 mg/m2 dose.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Dentistry, Oral Surgery and Medicine
Preview
A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma
Authors
, , ,